Veracyte, Inc.
VCYT
Rank in Stocks
#4244
Veracyte, Inc. operates as a diagnostics company in the United States and... Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Share Price
$46.05
Last synced: 2026-10-21
Market Cap
$3.70B
Change (1 day)
2.81%
Change (1 year)
32.51%
Country
US
Trade Veracyte, Inc. (VCYT)
Category
Healthcare
Stock price history for Veracyte, Inc. (VCYT)
Highest end of day price: $44.47 on 2026-10-01
Lowest end of day price: $12.82 on 2013-10-01
Lowest end of day price: $12.82 on 2013-10-01
Stock price history of Veracyte, Inc. from 2013 to 2026
Annual Stock Price Performance
| Year | Performance |
|---|---|
| 2026 (TTM) | -2.90% |
| 2025 | 3.85% |
| 2024 | 55.02% |
| 2023 | 1.26% |
| 2022 | -33.63% |
| 2021 | -25.42% |
| 2020 | 88.25% |
| 2019 | 137.21% |
| 2018 | 87.23% |
| 2017 | -13.42% |
| 2016 | 5.54% |
| 2015 | -8.13% |
| 2014 | -43.76% |
| 2013 | 0.00% |
Stock price for similar companies or competitors
| Company | Stock price | Change 1y% | Country |
|---|---|---|---|
| $694.53 | 22.45% |
US
|
|
| $234.00 | 7.29% |
US
|
|
| $416.01 | 121.26% |
US
|
|
| $21.28 | 50.29% |
CN
|
|
| $177.93 | 21.98% |
US
|
